Rockefeller Capital Management L.P. purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 17,814 shares of the biopharmaceutical company’s stock, valued at approximately $1,343,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Heritage Wealth Advisors grew its position in shares of Gilead Sciences by 2.5% during the fourth quarter. Heritage Wealth Advisors now owns 26,523 shares of the biopharmaceutical company’s stock worth $1,903,000 after purchasing an additional 642 shares in the last quarter. Hanson & Doremus Investment Management grew its position in shares of Gilead Sciences by 35.7% during the fourth quarter. Hanson & Doremus Investment Management now owns 2,461 shares of the biopharmaceutical company’s stock worth $176,000 after purchasing an additional 648 shares in the last quarter. Griffin Asset Management Inc. grew its position in shares of Gilead Sciences by 2.5% during the fourth quarter. Griffin Asset Management Inc. now owns 27,160 shares of the biopharmaceutical company’s stock worth $1,946,000 after purchasing an additional 650 shares in the last quarter. First Capital Advisors Group LLC. grew its position in shares of Gilead Sciences by 9.1% during the fourth quarter. First Capital Advisors Group LLC. now owns 7,857 shares of the biopharmaceutical company’s stock worth $563,000 after purchasing an additional 653 shares in the last quarter. Finally, Wedbush Securities Inc. grew its position in shares of Gilead Sciences by 1.0% during the fourth quarter. Wedbush Securities Inc. now owns 65,102 shares of the biopharmaceutical company’s stock worth $4,664,000 after purchasing an additional 660 shares in the last quarter. Institutional investors and hedge funds own 77.72% of the company’s stock.

In related news, EVP Gregg H. Alton sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 1st. The stock was sold at an average price of $78.69, for a total transaction of $1,967,250.00. Following the completion of the sale, the executive vice president now directly owns 69,426 shares of the company’s stock, valued at approximately $5,463,131.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Robin L. Washington sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $80.31, for a total value of $401,550.00. Following the sale, the chief financial officer now directly owns 23,749 shares of the company’s stock, valued at $1,907,282.19. The disclosure for this sale can be found here. Insiders have sold a total of 226,667 shares of company stock valued at $17,060,854 over the last three months. 1.30% of the stock is owned by corporate insiders.

NASDAQ:GILD opened at $67.53 on Friday. The company has a market capitalization of $88.64 billion, a PE ratio of 7.89, a P/E/G ratio of -5.93 and a beta of 1.19. Gilead Sciences, Inc. has a 1 year low of $63.76 and a 1 year high of $89.54. The company has a debt-to-equity ratio of 1.32, a current ratio of 2.84 and a quick ratio of 2.75.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, May 1st. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.67 by ($0.19). The company had revenue of $5.09 billion during the quarter, compared to the consensus estimate of $5.40 billion. Gilead Sciences had a net margin of 14.03% and a return on equity of 45.49%. Gilead Sciences’s revenue for the quarter was down 21.8% on a year-over-year basis. During the same period in the previous year, the business earned $2.23 earnings per share. research analysts expect that Gilead Sciences, Inc. will post 5.75 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 28th. Investors of record on Friday, June 15th will be paid a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.38%. The ex-dividend date is Thursday, June 14th. Gilead Sciences’s dividend payout ratio is currently 26.64%.

Several research firms have weighed in on GILD. BidaskClub cut Gilead Sciences from a “sell” rating to a “strong sell” rating in a report on Friday, May 4th. Barclays cut their price target on Gilead Sciences from $95.00 to $90.00 and set a “buy” rating for the company in a report on Wednesday, May 2nd. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Wednesday, May 2nd. Leerink Swann set a $72.00 price target on Gilead Sciences and gave the company a “market perform” rating in a report on Wednesday, May 2nd. Finally, Zacks Investment Research cut Gilead Sciences from a “buy” rating to a “hold” rating in a report on Monday, May 7th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. Gilead Sciences currently has an average rating of “Buy” and a consensus target price of $88.14.

Gilead Sciences Company Profile

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.